Beneficial effects | |
At alpha-1 receptor: | |
Increased vasoconstriction (at low doses) | |
Increased peripheral vascular resistance | |
Increased blood pressure | |
Decreased mucosal edema (eg, in larynx) | |
At beta-1 receptor: | |
Increased heart rate (chronotropy) | |
Increased force of cardiac contraction (inotropy) | |
At beta-2 receptor: | |
Decreased mediator release from mast cells and basophils | |
Increased bronchodilation | |
Increased vasodilation | |
Adverse effects*¶Δ | |
Common and transient | Anxiety, palpitations, pallor, tremor, fear, restlessness, dizziness, headache |
Uncommon (typically occur after overdose) | Ventricular arrhythmias, angina, myocardial infarction, pulmonary edema, sudden sharp increase in blood pressure, intracranial hemorrhage |
¶ Serious adverse effects such as those listed in the table potentially occur when epinephrine is given in overdose by any route, most commonly after an intravenous bolus injection, an overly rapid intravenous infusion, or an erroneous intravenous injection of a 1 mg/mL (1:1000) epinephrine solution instead of an appropriately diluted 0.1 mg/mL (1:10,000) or a 0.01 mg/mL epinephrine solution.
Δ Anaphylaxis can present as an acute coronary syndrome, arrhythmias, myocardial infarction, or angina, before or in the absence of epinephrine injection. This potentially occurs in patients with known coronary artery disease, patients in whom subclinical coronary artery disease is unmasked, and patients (including children) with transient coronary artery vasospasm in whom no cardiovascular abnormalities can be detected by electrocardiogram or echocardiography after recovery from anaphylaxis.